Skip to main content
Clinical Trials/NCT05449782
NCT05449782
Completed
Not Applicable

Proof-of-concept Study to Investigate Hand and Foot Microvascular Response to Cocoa Flavanols in Healthy and Type 2 Diabetes Participant

University of Surrey1 site in 1 country22 target enrollmentMay 17, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Microangiopathy, Diabetic
Sponsor
University of Surrey
Enrollment
22
Locations
1
Primary Endpoint
Macrovascular endothelial function
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The greatest challenge in our ageing society are cardiovascular diseases such as stroke, heart attack, peripheral artery disease of the legs with non-healing wounds (ulcers), or diabetes. Specific diets with high polyphenol content are associated with lower incidence of cardiovascular disease and can improve macrovascular function when consumed acutely and chronically. Which role the smallest blood vessels (microcirculation) play in this and if the microcirculation responds to therapies is not well understood. One reason for this is that no generally available medical instrument has the resolution to study the microcirculation. The recently developed optical coherence tomography angiography (OCTA), currently mainly used by eye doctors, is able to visualise the microcirculation.

The current randomised controlled cross-over proof-of-concept study will test the acute effect of a cocoa flavanol intervention on cutaneous microvascular structure and function of hands and feet together with macrovascular function of upper and lower extremities in healthy and type 2 diabetes participants. It is the hypothesis that cocoa flavanol intervention as compared to placebo can acutely increase microvascular vasodilation and macrovascular endothelial function in arms and legs together with arterial stiffness in both healthy and type 2 diabetes participants.

Registry
clinicaltrials.gov
Start Date
May 17, 2021
End Date
May 17, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy, 20-70 years
  • BMI 20-30 kg/m\^2

Exclusion Criteria

  • Diabetes mellitus
  • Symptoms of acute infection
  • Cardiac rhythm other than sinus
  • Active malignancy
  • Clinical signs or symptoms of cardiovascular disease (coronary artery disease, lower extremity artery disease, cerebrovascular disease): angina pectoris, dyspnea, palpitation, syncope, claudication
  • Active vasoactive medication.
  • Type 2 Diabetes:
  • Inclusion Criteria:
  • Type 2 diabetes mellitus
  • 20-70 years

Outcomes

Primary Outcomes

Macrovascular endothelial function

Time Frame: Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo

Flow-mediated dilation determined with ultrasound in brachial and common femoral artery

Microvascular dilation

Time Frame: Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo

Microvascular diameter increase in response to 5 min limb occlusion on hands and feet

Secondary Outcomes

  • Blood pressure(Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo)
  • Arterial stiffness(Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo)
  • Leg perfusion pressure(Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo)

Study Sites (1)

Loading locations...

Similar Trials